India, Nov. 9 -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, on Monday, reported third quarter earnings that surged from last year on significant growth in revenue. The company said it expects positive adjusted EBITDA for the fiscal 2026 and lifted revenue outlook for the period.
The third quarter net income totaled $6.952 million, or $0.17 per share, compared to $0.830 million, or $0.02 per share, a year ago.
Adjusted EBITDA for the quarter was $11.5 million, compared to $5.3 million in the previous year.
Gross margins improved to 89%, from 87% in the third quarter of 2025.
Total revenue for the quarter was $35.102 million, up from $20.563 million la...